SCI Abstract

search
Gepotidacin: First Approval
Gepotidacin: First Approval
Gepotidacin (BLUJEPA), a small molecule triazaacenaphthylene bacterial type II topoisomerase inhibitor (BTI) antibacterial...
Nipocalimab: First Approval
Nipocalimab: First Approval
Nipocalimab (nipocalimab-aahu; IMAAVY™) is a fully human monoclonal antibody that binds to and blocks the neonatal f...
Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management
Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management
Insulin icodec (icodec) is a first-in-class once-weekly basal insulin approved for the treatment of adults with type 1 dia...
PCSK9 Inhibitors: A Potential Priority Choice for Lipid Management in Patients with Diabetic Kidney Disease
PCSK9 Inhibitors: A Potential Priority Choice for Lipid Management in Patients with Diabetic Kidney Disease
Diabetic kidney disease (DKD), a severe microvascular complication of diabetes mellitus (DM), is the predominant cause of ...
Managing Burning Mouth Syndrome: Current and Future Directions
Managing Burning Mouth Syndrome: Current and Future Directions
Burning mouth syndrome (BMS) is a chronic pain condition characterized by a persistent burning sensation in the oral mucos...
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy
Measurable (or minimal) residual disease (MRD) testing offers critical prognostic insight in multiple myeloma (MM), surpas...
Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review
Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review
Our objective was to systematically synthesize and evaluate the existing evidence from meta-syntheses (systematic reviews ...
Update on Medical Treatment of Cushing’s Syndrome
Update on Medical Treatment of Cushing’s Syndrome
First-line treatment of endogenous Cushing’s syndrome (CS) is surgical removal of the tumor responsible for cortisol...
The Road to Remyelination in Multiple Sclerosis: Breakthroughs, Challenges, and Considerations for Future Trial Design
The Road to Remyelination in Multiple Sclerosis: Breakthroughs, Challenges, and Considerations for Future Trial Design
Despite major advances in multiple sclerosis (MS) treatment, disability accumulation independent of relapse activity remai...
Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition
Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition
Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra-rare acquired genetic stem cell disorder based on a mutation in the...
Long non-coding RNA LRTOR drives osimertinib resistance in non-small cell lung cancer by boosting YAP positive feedback loop
Volume 83, November 2025, 101245Author links open overlay panel, , , , , , , , , , , , , , , , , , , AbstractThe therapeut...
Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy
ALG8alpha-1,3-glucosyltransferase 8ANRILantisense noncoding RNA at the INK4 locusASOantisense oligonucleotidesATMataxia-te...
HSA-templated synergistic platform boosts radiotherapy via enhanced radiosensitization and ferroptosis induction
Radiotherapy efficacy in cancer treatment is frequently compromised by tumor radioresistance, limited immune activation, a...
RNF217-KEAP1-NRF2 feedback loop confers therapeutic resistance by inhibiting ferroptosis in esophageal squamous cell carcinoma
Esophageal cancer is one of the most common malignant tumors and the seventh leading cause of cancer-related deaths worldw...
Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance
Volume 83, November 2025, 101277Author links open overlay panel, , , , , , , AbstractResistance to cancer therapy is drive...
EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets
Recent advancements in oncology and biology, along with the emergence of innovative techniques such as next-generation seq...
Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy
Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the uncontrolled clonal expansion ...
Emerging role of sialylation in cancer therapy resistance: Mechanisms and therapeutic implications
ALKAnaplastic lymphoma kinaseBACE1Beta-site amyloid precursor protein-cleaving enzymeBCP-ALLB-cell precursor acute lymphob...
The role of synthetic lethality in overcoming cancer therapy resistance: Emerging paradigm and recent advances
Cancer remains a leading cause of mortality worldwide, posing a significant challenge to human health. Despite remarkable ...
Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions
Targeting DNA damage response (DDR) pathways has become a promising strategy for overcoming tumor drug resistance, particu...
Overcoming delivery challenges of antimicrobial peptides for clinical translation: From nanocarriers to molecular modifications
Since Alexander Fleming's discovery of penicillin in 1928, antibiotics have played a crucial role in saving lives and ushe...
Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesis
Volume 84, January 2026, 101299Author links open overlay panel, , , , , , AbstractBackgroundResistance to Bevacizumab (Bev...
Navigating Medical Device Safety: Current Status, Challenges, and Future Regulatory Directions
Navigating Medical Device Safety: Current Status, Challenges, and Future Regulatory Directions
Medical devices are indispensable in modern healthcare. They enable the prevention, diagnosis, and treatment of diseases w...